The chromosome 17q21 locus is the most consistently replicated genetic risk region for childhood-onset asthma. The locus spans a dense 130-kb regulatory haploblock containing six genes — IKZF3, ZPBP2, GSDMB, ORMDL3, LRRC3C, and GSDMA — and harbors a cluster of correlated variants that collectively regulate ORMDL3 expression in airway tissue and immune cells. rs11650680 is an intronic regulatory variant within this haploblock that was identified alongside rs7216389 in the original landmark GWAS¹¹ original landmark GWAS
Moffatt et al. Nature 2007, 994 childhood asthma cases vs 1,243 controls; rs11650680 and rs7216389 were among the top index SNPs at 17q21, p<10⁻¹². Unlike rs7216389 (where T is the risk allele), rs11650680 has the C allele as the risk allele and the T allele as the protective variant — a subtle but important distinction established by multiple meta-analyses.

The Mechanism

rs11650680 sits within an intron of the ORMDL3/GSDMB locus and functions as a regulatory eQTL²² regulatory eQTL
expression quantitative trait locus — a variant that alters nearby gene transcript levels without changing the protein sequence; rs11650680 modulates ORMDL3 and GSDMB expression in a C-allele-dose-dependent manner. The C allele is associated with higher ORMDL3 expression in airway epithelial cells and lymphoblastoid cell lines. Elevated ORMDL3 inhibits serine palmitoyltransferase, reducing de novo ceramide and sphingolipid synthesis in the airway epithelium. This sphingolipid deficit lowers T-cell activation thresholds, promotes Th2-skewed immune polarization, and activates the ATF6 branch of the unfolded protein response — collectively amplifying the eosinophilic airway inflammation that characterises asthma.

The T allele, by contrast, is associated with lower ORMDL3 expression³³ lower ORMDL3 expression
the T allele at rs11650680 reduces the C-allele-driven regulatory signal, producing less ORMDL3 mRNA in airway tissue and immune cells, and corresponds to the lowest asthma susceptibility at this locus. Carriers of one or two T alleles (CT and TT genotypes) produce less ORMDL3 and show correspondingly lower markers of airway eosinophilic inflammation than CC homozygotes.

The Evidence

The Shi et al. 2015 meta-analysis⁴⁴ Shi et al. 2015 meta-analysis
13 published case-control studies, 6,462 asthma cases and 7,357 controls; fixed-effects model; rs11650680 T allele significantly protective in dominant model (TT+CT vs. CC) established the asthma-protective role of the T allele across multiple populations. A second meta-analysis pooling 18 studies and 7,904 cases with 10,874 controls⁵⁵ pooling 18 studies and 7,904 cases with 10,874 controls
Wan et al. Human Immunology 2014, rs11650680 and rs12603332 T alleles both protective, consistent across Caucasian and Asian subgroups replicated the finding.

Population-specific data reveals important variation. A study of 315 Chinese children (315 asthma cases, 192 controls; Leung et al. Allergy 2009)⁶⁶ (315 asthma cases, 192 controls; Leung et al. Allergy 2009)
rs11650680 significantly associated with asthma diagnosis, atopy, and total plasma IgE levels (p=0.008–0.0002) in Chinese children; the CC risk genotype correlated with higher IgE burden and atopic sensitisation demonstrated that the rs11650680 locus affects not only asthma diagnosis but also atopic sensitisation and IgE production — linking the variant to the broader Th2-driven atopic phenotype beyond asthma alone.

In Japanese women, the CT heterozygous genotype was significantly inversely associated with asthma⁷⁷ CT heterozygous genotype was significantly inversely associated with asthma
Miyake et al. DNA Cell Biol 2014, 202 asthma cases and 1,290 controls in the KOMCHS cohort; CT vs. CC OR 0.67 (95% CI 0.46–0.96); effect was specific to adult-onset asthma, consistent with the meta-analysis direction. Separately, Acosta-Perez et al. 2012⁸⁸ Acosta-Perez et al. 2012
JACI, Puerto Rican and Mexican children; CC genotype associated with higher eosinophil-associated biomarkers and bronchial hyperresponsiveness, consistent with elevated ORMDL3-driven eosinophilic inflammation extended the finding to Latino populations.

Practical Implications

The CC genotype is the most common globally (~69%) and represents the reference state for this variant — but it also carries elevated asthma susceptibility. For CC individuals with asthma, the clinical picture is one of elevated eosinophilic airway inflammation driven by increased ORMDL3 activity: monitoring FeNO and blood eosinophil counts helps characterize the inflammatory endotype and guide treatment. For TT and CT carriers, the T allele provides partial to complete attenuation of the ORMDL3-driven airway inflammatory signal.

The rs11650680 signal is partially correlated with rs7216389 and rs12936231, and these SNPs likely tag overlapping but not fully redundant regulatory elements within the 17q21 haploblock. Carrying the protective T allele at rs11650680 does not eliminate risk conferred by other 17q21 variants, so the broader haploblock context matters for a complete risk picture.

Interactions

rs11650680 lies in strong LD with rs7216389 and rs12936231 within the same 17q21 haploblock, but the LD is incomplete — some individuals carry discordant genotypes across these three SNPs, suggesting partially independent regulatory signals. The combination of the CC genotype at rs11650680, the TT genotype at rs7216389, and the CC genotype at rs12936231 represents full engagement of the ORMDL3-overexpressing regulatory state; individuals with this haplotype combination have the highest ORMDL3 expression and the greatest airway inflammatory burden. The 17q21 locus also shows a well-documented inverse relationship with autoimmune disease risk⁹⁹ inverse relationship with autoimmune disease risk
the asthma-risk haplotype (high ORMDL3) is associated with lower risk of type 1 diabetes and Crohn's disease; the autoimmune-risk allele at rs2872507 is protective for asthma — reflecting the Th1/Th17 vs. Th2 immune axis trade-off.

About one in three people is highly susceptible to motion sickness. For decades this variation was assumed to be mostly psychological or a matter of inner-ear anatomy, but the first genome-wide association study of motion sickness¹¹ first genome-wide association study of motion sickness
Hromatka et al. Genetic variants associated with motion sickness point to roles for inner ear development, neurological processes and glucose homeostasis. Human Molecular Genetics, 2015 — in 80,494 individuals from 23andMe — showed the difference is partly genetic, and one of the strongest signals sits inside NLGN1, the gene that builds neuroligin 1.

rs11713169 is an intronic variant within NLGN1 on chromosome 3 (3q26.31). The C allele reached genome-wide significance (P = 5.9×10⁻¹³, beta = 0.052) for increased motion sickness susceptibility. The C allele is present in about 15% of Europeans and only 3% of Africans; roughly 75% of people globally carry two A alleles and have no elevated genetic susceptibility from this locus.

The Mechanism

Neuroligin 1²² Neuroligin 1
NL1, encoded by NLGN1, is a postsynaptic transmembrane cell adhesion protein found exclusively at excitatory (glutamatergic) synapses. Its extracellular domain binds presynaptic β-neurexins³³ β-neurexins
a family of presynaptic cell adhesion molecules that form the trans-synaptic bridge required for synapse formation and maturation, creating the structural bridge that recruits and aligns NMDA and AMPA receptors at the postsynaptic density.

Wu et al. 2019⁴⁴ Wu et al. 2019
Neuroligin-1 Signaling Controls LTP and NMDA Receptors by Distinct Molecular Pathways. Neuron demonstrated that NL1 performs two mechanistically separate functions: its intracellular domain maintains baseline NMDA receptor levels at the synapse, while its trans-synaptic neurexin interaction is required for NMDA-dependent long-term potentiation (LTP) and dendritic spine expansion. Deleting NL1 abolishes the structural plasticity associated with LTP. This places NL1 directly at the intersection of synapse maintenance and activity-dependent learning.

Motion sickness habituation — the process by which the brain learns to suppress nausea responses after repeated exposure to provocative motion — requires exactly this kind of NMDA-dependent synaptic plasticity. Vestibular nucleus neurons undergo NMDA receptor-driven CREB activation and upregulate inhibitory GABAA receptors⁵⁵ Vestibular nucleus neurons undergo NMDA receptor-driven CREB activation and upregulate inhibitory GABAA receptors
Wang et al. 2012, Brain Research during repeated rotation training, while hippocampal CA1 encodes the stored motion pattern via CaMKII/CREB signaling⁶⁶ hippocampal CA1 encodes the stored motion pattern via CaMKII/CREB signaling
Wang et al. 2017, Scientific Reports — allowing the nervous system to anticipate rather than react to familiar motion. NLGN1 variation that subtly alters NMDA-dependent plasticity at excitatory synapses throughout these circuits is a plausible mechanism for the observed genetic effect on habituation efficiency.

The Evidence

The signal at rs11713169 emerged from the Hromatka et al. 2015 GWAS⁷⁷ Hromatka et al. 2015 GWAS
Human Molecular Genetics of 80,494 individuals — the first and largest genetic study of motion sickness ever conducted. The study identified 35 SNPs at genome-wide significance (P < 5×10⁻⁸), and rs11713169 was among the strongest hits (P = 5.9×10⁻¹³). The authors grouped associated genes into three categories: balance and vestibular development (PVRL3, TSHZ1), neurological processes including central habituation (NLGN1), and glucose homeostasis. The study also documented sex-specific effects, with up to three times stronger genetic effects in women than men at some loci.

The evidence for NL1's specific molecular role in excitatory synaptic plasticity is substantial and converges from multiple independent laboratories and model systems, supporting the mechanism by which intronic NLGN1 variation would modulate motion sickness susceptibility through altered synaptic plasticity efficiency in vestibular and hippocampal circuits.

Practical Actions

Motion sickness has effective management strategies that work independently of genotype — but knowing you carry the C allele provides a biological reason to invest in them proactively. H1-antihistamines (dimenhydrinate, meclizine) are the primary pharmacological option; they block histaminergic vestibular-cerebellar signalling that amplifies the sensory-mismatch response.

Habituation remains the most effective non-pharmacological approach⁸⁸ Habituation remains the most effective non-pharmacological approach
Keshavarz & Golding 2022, Current Opinion in Neurology. Graded exposure — beginning with mild motion and progressively increasing challenge over days to weeks — builds the stored internal motion model in hippocampal circuits. An important caveat: medications that suppress symptoms during exposure can slow habituation. If your goal is long-term adaptation rather than single-event relief, graded unmedicated exposure is more effective than relying on antihistamines.

Interactions

The GWAS that identified rs11713169 also found rs10514168 (near TSHZ1) as a motion-sickness locus via vestibular development pathways. Both variants contribute additively to susceptibility through different mechanisms — rs10514168 via inner-ear development and rs11713169 via central synaptic habituation. Carrying risk alleles at both loci further elevates baseline susceptibility.

Sex modifies the effect: the Hromatka study found effects up to three times stronger in women at some motion-sickness loci. Whether rs11713169 specifically shows a sex-stratified effect was not individually reported for this variant.

Peroxisome proliferator-activated receptor gamma (PPARγ) is the master transcriptional regulator of fat cell development and a central node in insulin sensitivity¹¹ insulin sensitivity
PPARγ activates hundreds of genes controlling fatty acid uptake, lipid storage, and glucose homeostasis in adipose tissue, liver, and muscle. rs1175543 is a common intronic variant in PPARG — one of several non-coding variants across the gene that tag functional haplotypes influencing downstream metabolic risk.

The Mechanism

rs1175543 sits deep in intron 9 of PPARG at GRCh38 chr3:12,424,933 (A>G substitution). It does not change any amino acid. Instead, its relevance is primarily as a haplotype marker: it is in strong linkage disequilibrium²² strong linkage disequilibrium
Linkage disequilibrium (LD) means two variants are so physically close on the chromosome that they are nearly always inherited together; D'=97 indicates near-complete co-inheritance with rs709158 (D' = 0.97) and with rs1797912 and rs12490265, forming a haplotype block that may influence PPARγ expression, splicing efficiency, or enhancer activity in metabolically active tissues. The precise regulatory mechanism has not been characterized at the molecular level, but intronic PPARG variants in this block have been shown to affect adipogenesis-related gene networks in population studies.

The Evidence

A case-control study in 489 Kazakh subjects³³ case-control study in 489 Kazakh subjects
Guo et al. Analysis of the haplotype and linkage disequilibrium of PPARγ gene polymorphisms rs3856806, rs12490265, rs1797912, and rs1175543 among patients with metabolic syndrome in Kazakh of Xinjiang Province. Genet Mol Res, 2014 found that the rs1175543 G allele frequency was significantly lower in metabolic syndrome patients than in controls (40.61% vs 47.54%, P = 0.029), suggesting that G carriers are less likely to develop metabolic syndrome. The AGCC haplotype (incorporating rs1175543G) emerged as a protective factor.

A large prospective cohort study in Washington County, Maryland⁴⁴ prospective cohort study in Washington County, Maryland
Gallicchio et al. Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality. PPAR Res, 2008 tracked 9,364 Caucasian participants for over a decade and found a significant age-adjusted association between rs1175543 and baseline total cholesterol levels. No association with cardiovascular events or all-cause mortality was detected over the follow-up period, suggesting the variant's influence is metabolic rather than directly cardiovascular.

The evidence for rs1175543 as an independent functional variant is emerging: the metabolic syndrome association derives from a single study in one ethnic group, and the cholesterol signal has not been replicated in a separate large-scale GWAS. The variant's biological significance is best understood as part of the broader PPARG haplotype block rather than as a stand-alone risk allele.

Practical Actions

Carriers of the G allele — particularly GG homozygotes — appear to have a modestly favorable metabolic profile compared to AA homozygotes. For AA carriers, the modest risk signal at this locus is best addressed through interventions known to support PPARγ pathway health: managing dietary fat composition and monitoring key metabolic markers that track insulin-related risk.

Interactions

rs1175543 is in very strong LD with rs709158 and moderate LD with rs1797912 and rs12490265 — all intronic PPARG variants. These SNPs collectively form a haplotype block, and the protective haplotypes (AGCC, GAAT) appear to confer a combined effect greater than any single variant alone. rs1175543 should always be interpreted alongside the canonical PPARG Pro12Ala variant (rs1801282), which has established evidence for insulin sensitivity effects. Carriers of both the AA genotype at rs1175543 and the CC genotype at rs1801282 (Pro/Pro) accumulate the most PPARG-related metabolic risk across this gene.

Apolipoprotein B (apoB) is the structural backbone of every LDL, VLDL, and chylomicron particle your liver makes. Without a full-length apoB-100, your liver cannot build and secrete normal LDL particles, so your circulating LDL cholesterol stays characteristically and permanently low¹¹ characteristically and permanently low
Heterozygous FHBL carriers almost always have LDL-C below 70 mg/dL regardless of diet, a lifelong trait caused by the variant, not by healthy lifestyle. This sounds like good news — and for cardiovascular health, it mostly is — but the same impaired lipid-export machinery creates two clinically relevant risks: fat accumulation in the liver and impaired transport of fat-soluble vitamins.

The Mechanism

The R2522X variant introduces a premature stop codon at amino acid 2,522 of the 4,536-amino-acid apoB-100 protein (c.7564C>T on the coding strand; G>A on the GRCh38 plus strand). The resulting truncated protein — called apoB-55²² apoB-55
The "55" refers to the fact that the truncated protein is approximately 55% the length of full-length apoB-100 — comprises about 55% of the normal protein length and is secreted at roughly 37–40% of the normal molar rate compared to wild-type apoB-100, consistent with the linear relationship between truncation length and secretion efficiency demonstrated by Parhofer et al.³³ demonstrated by Parhofer et al.
Parhofer et al. Positive linear correlation between the length of truncated apolipoprotein B and its secretion rate. J Lipid Res, 1996. The half of the protein that is missing includes domains critical for maximal lipid recruitment into the lipoprotein particle core.

Because apoB is the only structural protein on LDL particles, each cell carries one normal APOB allele and one truncating allele. The liver produces both full-length apoB-100 and the shorter apoB-55, but the truncated version carries less lipid cargo per particle, and fewer lipid-laden particles leave the liver — so hepatocytes accumulate triglycerides that cannot be exported.

The Evidence

The R2522X variant was first identified in the early 1990s in patients with unexplained low cholesterol. The same CGA→TGA change at the CpG dinucleotide hot spot in exon 26 was later independently rediscovered in a second kindred by Gabelli et al.⁴⁴ Gabelli et al.
Gabelli et al. Diabetes mellitus in a new kindred with familial hypobetalipoproteinemia and an apolipoprotein B truncation (apoB-55). Atherosclerosis, 1998, whose proband had LDL-C of 44 mg/dL and detectable plasma apoB-55 on immunoblotting. Notably, the proband and his father both had type 2 diabetes, yet neither had clinically manifest macrovascular complications — consistent with the cardiovascular-protective effect of lifelong low LDL-C.

The apoB-55 truncation falls in a zone where the protein can still be secreted and detected in plasma (unlike very short truncations below ~apoB-30, which are not detectable in plasma at all). Its secretion efficiency of ~37% of normal means heterozygotes lose roughly a third of their normal VLDL export capacity, explaining the 3-to-5-fold increase in hepatic fat content that characterizes FHBL, as reviewed by Schonfeld⁵⁵ Schonfeld
Schonfeld G. Familial hypobetalipoproteinemia: a review. J Lipid Res, 2003.

A systematic literature review by Molk et al.⁶⁶ Molk et al.
Molk et al. Non-alcoholic fatty liver disease in a pediatric patient with heterozygous familial hypobetalipoproteinemia due to a novel APOB variant. Front Med, 2023 confirms that fatty liver disease occurs even in heterozygous carriers and can present in childhood. About 5–10% of heterozygous FHBL individuals develop more severe nonalcoholic steatohepatitis requiring medical attention.

Practical Actions

For heterozygous carriers the most important immediate step is establishing a baseline: a fasting lipid panel confirms the expected low LDL-C and rules out concurrent dyslipidemia; liver enzymes (AST/ALT) and a hepatic ultrasound screen for steatosis; and serum levels of vitamins A, D, E, and K evaluate fat-soluble vitamin status. Because apoB-containing lipoprotein particles are the primary carriers of fat-soluble vitamins from the gut into circulation, impaired VLDL/chylomicron secretion can subtly reduce vitamin transport even when dietary intake is adequate. Supplementation with water-dispersible or emulsified forms of vitamins D, E, A, and K corrects any measured deficiency efficiently.

Dietary saturated fat restriction is not the goal here (unlike APOE4) — in fact, very low fat diets can worsen fat-soluble vitamin absorption. The aim is identifying and correcting any subclinical deficiency before it causes neurological or ophthalmological consequences.

Cardiovascular risk is paradoxically reduced: lifelong LDL-C below 70 mg/dL confers protection against atherosclerosis, and carriers need not take statins for lipid-lowering purposes. However, the reduced LDL does not protect against the metabolic consequences of obesity or insulin resistance, so maintaining a healthy metabolic profile remains relevant.

Interactions

In the rare case of a compound heterozygote or homozygote for APOB loss-of-function variants, the phenotype resembles abetalipoproteinemia (severe fat malabsorption, acanthocytosis, retinitis pigmentosa, progressive ataxia). Interaction with APOE genotype (rs429358, rs7412) is worth noting conceptually: APOE4 would ordinarily raise LDL cholesterol, but an APOB truncating variant overrides this by limiting the number of LDL particles produced rather than their clearance rate. The net effect in a double carrier would still be low LDL-C, driven by impaired production.

While most pharmacogenomic attention focuses on loss-of-function variants, the CYP2C19*17 allele¹¹ rs12248560 represents the opposite end of the spectrum: a gain-of-function variant that increases enzyme activity beyond normal levels. This variant sits in the promoter region and upregulates CYP2C19 gene expression.

The Mechanism

The rs12248560 variant²² C>T at position -806 in the promoter region alters a transcription factor binding site in the CYP2C19 promoter, increasing gene expression by approximately 2-fold. More enzyme means faster metabolism of all CYP2C19 substrates. Homozygous carriers (TT) are classified as ultrarapid metabolizers, while heterozygous carriers (CT) are rapid metabolizers. The variant was first characterized by Sim et al. in 2006³³ Sim et al. in 2006
Sim SC et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism. Clin Pharmacol Ther, 2006.

Clinical Implications

For proton pump inhibitors (PPIs), rapid and ultrarapid metabolizers break down the drug too quickly, potentially leading to inadequate acid suppression. Standard PPI doses may not effectively control acid reflux or heal ulcers. Higher doses or alternative medications may be needed. The CPIC guideline for PPIs⁴⁴ CPIC guideline for PPIs
Lima JJ et al. CPIC guideline for CYP2C19 and proton pump inhibitor dosing. Clin Pharmacol Ther, 2021 recommends increasing PPI doses by 50-100% for ultrarapid metabolizers.

For clopidogrel, increased CYP2C19 activity is actually beneficial because more prodrug gets converted to the active metabolite, enhancing the antiplatelet effect. However, this could theoretically increase bleeding risk.

The Diplotype Complexity

Your overall CYP2C19 status depends on the combination of both alleles. Someone carrying *2/*17 (one loss-of-function, one gain-of-function) presents a classification challenge - current guidelines generally classify this as intermediate metabolizer status, though the clinical impact may vary by medication.

Practical Considerations

If you are a rapid or ultrarapid metabolizer, pay attention to PPI effectiveness. If standard doses of omeprazole or pantoprazole do not adequately control your acid reflux symptoms, your CYP2C19 genotype may be the reason. Discuss with your doctor about dose adjustments or alternative acid-suppressing medications that are not CYP2C19 substrates.

Nucleobindin-2 (NUCB2) encodes the precursor protein that is proteolytically cleaved to release nesfatin-1¹¹ nesfatin-1
An 82-amino acid neuropeptide that suppresses appetite and modulates energy balance via melanocortin MC3/MC4 receptors and CRF2 — operates independently of the leptin pathway, a neuropeptide with broad roles in appetite suppression, glucose regulation, sleep-wake cycling, and — more recently discovered — cancer biology. The rs1330 variant sits within an intron of NUCB2 on chromosome 11 (GRCh38 position 17,294,482), meaning it does not alter the nesfatin-1 amino acid sequence directly. Instead, its effects are regulatory: the T allele is thought to influence NUCB2 splicing efficiency, transcript stability, or expression levels, though the precise molecular mechanism has not yet been resolved.

The T allele is the minor allele in most populations (~30–39% frequency globally, with notably lower frequency in African populations at ~17%). The reference C/C genotype represents wild-type nesfatin-1 expression; T allele carriers show associations across multiple disease contexts with a consistent direction — higher risk — though with sex-specific patterns that suggest hormonal context shapes how this intronic variant exerts its effects.

The Mechanism

As an intron variant, rs1330 does not change the nesfatin-1 peptide sequence. Its regulatory impact is inferred from its population-level associations. The T allele may alter the efficiency of RNA splicing at one of NUCB2's five transcript variants, reduce mRNA stability, or affect transcription factor binding in an intronic regulatory element — any of which would reduce the amount of functional NUCB2 protein available for cleavage into nesfatin-1. Reduced circulating nesfatin-1 is the common downstream consequence observed in obesity and insulin-resistant states across multiple NUCB2 studies, and the rs1330 T allele likely compounds this deficiency via a cis-regulatory mechanism.

The sex-specific pattern observed in the Zegers et al. obesity study²² Zegers et al. obesity study
Zegers D et al. Association between polymorphisms of the Nesfatin gene, NUCB2, and obesity in men. Mol Genet Metab, 2011 — where rs1330 associated with obesity only in males — and the reciprocal Li et al. T2D finding³³ Li et al. T2D finding
Li XS et al. NUCB2 polymorphisms are associated with an increased risk for type 2 diabetes in the Chinese population. Endocr Connect, 2020 in females (OR 1.31–1.42) may reflect estrogen and androgen modulation of NUCB2 expression. Estrogen upregulates nesfatin-1 production in certain hypothalamic circuits, potentially masking the effect of a reduced-expression variant in pre-menopausal women while leaving males more exposed to its impact on appetite and energy balance.

The Evidence

Obesity (males). The Zegers et al. 2011⁴⁴ Zegers et al. 2011
Zegers D et al. Association between polymorphisms of the Nesfatin gene, NUCB2, and obesity in men. Mol Genet Metab, 2011 case-control study genotyped 1,049 obese and 315 normal-weight Caucasian subjects across eight NUCB2 tagSNPs. Three variants — rs1330, rs214101, and rs757081 — showed association with obesity protection, but only in the male sub-analysis. Linear regression further linked rs1330 to BMI, body weight, and fat-free mass in men. This was the first evidence that NUCB2 intronic variants influence energy homeostasis in humans.

Type 2 diabetes (females). A Chinese Han study by Li et al. (2020)⁵⁵ Li et al. (2020)
Li XS et al. NUCB2 polymorphisms are associated with an increased risk for type 2 diabetes in the Chinese population. Endocr Connect, 2020 genotyped 578 T2DM patients against 1,609 healthy controls and identified rs1330 as significantly associated with T2DM risk in women (OR 1.31–1.42, P<0.05). The variant was also correlated with BMI in the female subpopulation, suggesting its influence spans both adiposity and glucose metabolism in women. No association was detected in men in this cohort — the reverse sex-specificity pattern from the Zegers obesity data.

Colorectal cancer. A Mexican cross-sectional study by Macías-Gómez et al. (2025)⁶⁶ Macías-Gómez et al. (2025)
Macías-Gómez NM et al. Variants in the neuropeptide gene NUCB2 as a possible biomarker for colorectal cancer. 2025 enrolled 397 CRC patients and 383 healthy controls. The TT genotype at rs1330 was significantly associated with colorectal cancer (OR 2.66, P<0.001), while CT heterozygotes showed an apparent protective pattern (OR 0.61), an unusual non-additive effect possibly reflecting over-dominant heterozygote advantage. Hardy-Weinberg deviation in the CRC group, however, warrants cautious interpretation.

Oral cancer. A Taiwanese cohort study by Yu et al. (2026)⁷⁷ Yu et al. (2026)
Yu CC et al. Association of NUCB2 genetic variants with the clinicopathological features of oral cancer. 2026 examined four NUCB2 polymorphisms in men with oral cancer. Compared to C/C wild-type, carriage of at least one T allele at rs1330 was associated with elevated risk of disease progression to stage III/IV, particularly in patients aged ≥60 years.

Sleep biology. rs1330 has not been studied directly in sleep GWAS, but the parent gene's sleep-regulatory role is established. In rat models, Vas et al. (2013)⁸⁸ Vas et al. (2013)
Vas S et al. Nesfatin-1/NUCB2 as a potential new element of sleep regulation in rats. PLoS One, 2013 demonstrated that central nesfatin-1 reduces REM sleep and increases wakefulness, and that hypothalamic NUCB2 expression declines during REM sleep deprivation and rebounds during recovery. Any NUCB2 variant that reduces nesfatin-1 output may therefore modulate sleep architecture, though this remains inferred biology at the rs1330 level.

Practical Implications

For CT and TT carriers, the most actionable implications are in metabolic monitoring and cancer awareness. Given the sex-specific patterns — obesity/BMI associations in males, T2D risk in females — sex-targeted monitoring is appropriate. Dietary interventions that support nesfatin-1 release, particularly high-protein morning meals, are theoretically beneficial but are based on functional biology rather than rs1330-specific trial data.

Interactions

rs1330 was identified in the same study (Zegers et al. 2011) as rs757081 and rs214101 — all three intronic and coding variants in NUCB2 showed male-specific obesity associations together, suggesting they may function as a regulatory haplotype influencing total NUCB2/nesfatin-1 output. Combined carriage of rs1330 T allele and rs757081 C allele (the obesity-risk form at the missense position) may additively reduce effective nesfatin-1 activity through both regulatory and protein-level mechanisms.

The interleukin-23 receptor (IL23R) gene encodes a key checkpoint in adaptive immunity. When IL-23 binds IL23R on T helper 17 (Th17) cells, it triggers STAT3 phosphorylation¹¹ STAT3 phosphorylation
STAT3 is a transcription factor that, once activated, drives production of the inflammatory cytokines IL-17A and IL-22, sustaining chronic inflammation in the gut, spine, and skin. The rs1343151 variant sits in an intron of IL23R at chromosome 1 position 67,253,446 (GRCh38) and carries no direct amino acid change. Its clinical significance comes from two distinct properties: it tags the protective IL23R haplotype that dampens Th17 responses in ankylosing spondylitis (AS) and inflammatory bowel disease (IBD), and it carries an independent association with rheumatoid arthritis (RA) susceptibility that operates through a separate biological mechanism.

The Mechanism

As an intronic variant, rs1343151 does not directly alter the IL-23 receptor protein. Instead, it acts as a tag SNP²² tag SNP
a variant that is inherited together with nearby functional variants so frequently that knowing its allele predicts those of its neighbours; here rs1343151 co-inherits with rs11465804 and the functional missense variant rs11209026 (R381Q) for the AS and IBD associations. The biological engine is the R381Q substitution at rs11209026: replacing arginine with glutamine at position 381 in the cytoplasmic tail of IL23R partially uncouples the receptor from JAK2/STAT3 signalling, reducing IL-17A output in Th17 effector cells from approximately 36 pg/ml to 5.5 pg/ml under IL-23 stimulation — a 6.5-fold reduction.

The RA association, by contrast, appears to be at least partially independent of the R381Q haplotype. Hollis-Moffatt et al. 2009³³ Hollis-Moffatt et al. 2009
Ann Rheum Dis; 3,000+ Caucasian RA cases and 3,800+ controls found no association of rs11209026 with RA (OR 1.01) while rs1343151 showed an OR of 1.14 in the same dataset — an unusual dissociation that suggests rs1343151 is tagging a different regulatory element or haplotype block for RA than for IBD and AS.

The Evidence

For Crohn's disease and ulcerative colitis, the protective effect of the A allele is well-replicated in European populations. A New Zealand cohort study (Ferguson et al. 2011⁴⁴ (Ferguson et al. 2011
Gastroenterol Res Pract; 339 CD cases, 407 controls) found an allelic OR of 0.68 (P=0.001), with AA homozygotes showing an OR of 0.29 (95% CI 0.16–0.53) relative to GG individuals — a striking 71% reduction in CD odds. A subsequent meta-analysis of 15 studies⁵⁵ meta-analysis of 15 studies
Ding et al. Sci Rep 2015 confirmed this with a pooled OR of 0.725 (95% CI 0.690–0.763) across Caucasian populations. Notably, no protective signal was detected in Asian populations, consistent with the low A allele frequency in East Asian cohorts (~8%).

For ankylosing spondylitis, a meta-analysis of 25 case-control studies⁶⁶ meta-analysis of 25 case-control studies
Zhong et al. Expert Rev Clin Immunol 2018; 8,431 AS cases, 8,972 controls confirmed that the A allele frequency was significantly lower in AS patients than controls (P<0.001), ranking rs1343151 among four IL23R polymorphisms with consistent protective signals against AS. The study-level OR for rs1343151 in an earlier meta-analysis of ankylosing spondylitis cohorts was approximately 0.68 (95% CI 0.55–0.83).

For rheumatoid arthritis, the picture reverses: the A allele is associated with a modest increase in RA risk (OR ~1.11–1.14 in Caucasians), which has been independently replicated across multiple cohorts. This disease-direction reversal at the same allele — protective for gut and spine inflammation, risky for synovial inflammation — reflects the differential roles of IL-23/Th17 signalling in different tissue compartments and disease pathologies.

Practical Implications

For individuals concerned about IBD or spondyloarthritis, the A allele at rs1343151 is a protective marker. AA homozygotes have substantially lower lifetime odds of Crohn's disease and ankylosing spondylitis than GG homozygotes, in parallel with other IL23R protective variants. For RA, the relationship inverts — carriers of the A allele have slightly elevated susceptibility. However, the absolute risk difference conferred by this single variant for RA is small (OR ~1.11) compared with the protective effect on IBD and AS (OR ~0.68–0.72). IL-23 pathway targeting (with biologics such as risankizumab or guselkumab) is highly effective for AS and CD; carriers of the GG genotype at rs1343151 — lacking the protective haplotype — may be among those most likely to benefit from such therapies if they develop these conditions.

Interactions

rs1343151 is in moderate-to-strong linkage disequilibrium with several other IL23R variants on chromosome 1p31.3, including rs11465804, rs10489629, and the functional missense variant rs11209026 (R381Q). For the IBD and AS associations, these variants are largely interchangeable as they tag the same protective haplotype block; a person carrying the protective A allele at rs1343151 will almost always also carry the protective alleles at rs11465804 and rs10489629.

The RA signal at rs1343151, being independent of rs11209026, represents a distinct haplotype association and likely reflects different regulatory architecture in synovial versus intestinal/entheseal immune environments. The IL23R susceptibility variants rs2201841 and rs1004819 tag a separate, risk-conferring haplotype block and are tracked individually in this database.

D-bifunctional protein (DBP), encoded by HSD17B4, is the enzymatic workhorse of peroxisomal beta-oxidation — the cellular pathway that shortens very long-chain fatty acids (VLCFAs), branched-chain fatty acids, and bile acid precursors that mitochondria cannot handle alone. The protein contains three sequentially arranged functional domains: a short-chain dehydrogenase/reductase unit, a 2-enoyl-CoA hydratase unit, and a sterol carrier protein 2 (SCP2) unit. Mutations in the hydratase domain cause type II DBP deficiency — an isolated block in the second step of peroxisomal beta-oxidation.

The N457Y variant is the second most common pathogenic mutation in HSD17B4¹¹ second most common pathogenic mutation in HSD17B4
Ferdinandusse et al. 2006 identified N457Y in 13 of 110 DBP-deficient patients, giving an allele frequency of ~11% among affected individuals, trailing only rs137853096 (p.Gly16Ser) in frequency. It was first characterized as a distinct disease entity by van Grunsven et al. in 1999.

The Mechanism

The N457Y substitution — asparagine to tyrosine at position 457 — falls within the 2-enoyl-CoA hydratase 2 unit²² 2-enoyl-CoA hydratase 2 unit
the enzyme that adds water across the double bond of enoyl-CoA substrates, converting them to 3-hydroxyacyl-CoA intermediates during each round of peroxisomal beta-oxidation. The bulky tyrosine side chain cannot accommodate the binding geometry required by the asparagine-containing pocket, leading to two compounding defects:

First, the full-length D-bifunctional protein is strongly destabilized. Second, the enoyl-CoA hydratase component that is normally cleaved from the full-length protein within peroxisomes becomes undetectable — the protein is degraded before it can be processed. The net effect is a near-complete block in the hydratase step, while the 3-hydroxyacyl-CoA dehydrogenase activity from the adjacent domain may be partially preserved. This biochemical profile defines type II DBP deficiency.

Because this variant specifically impairs the hydratase domain, the biochemical signature differs from total DBP deficiency: patients show elevated VLCFAs and branched-chain fatty acids (pristanic acid) but normal bile acid intermediates³³ patients show elevated VLCFAs and branched-chain fatty acids (pristanic acid) but normal bile acid intermediates
Bile acid synthesis uses a different step of the beta-oxidation cycle that requires the dehydrogenase unit, which is less affected in type II. This distinguishes type II DBP deficiency from the complete form and from Zellweger spectrum disorders.

The Evidence

DBP deficiency follows autosomal recessive inheritance. Two pathogenic alleles — either homozygous or compound heterozygous — are required to cause disease; single heterozygous carriers have normal peroxisomal function.

Van Grunsven et al. 1999⁴⁴ Van Grunsven et al. 1999 identified N457Y homozygous in two unrelated patients with isolated enoyl-CoA hydratase deficiency. Yeast expression studies confirmed the mutation was sufficient to cause the enzymatic defect. Both patients had severe neonatal presentations with hypotonia, seizures, and neuronal migration defects.

Mendes et al. 2015⁵⁵ Mendes et al. 2015 reported the first Portuguese case with homozygous N457Y: neonatal-onset seizures and hypotonia with neuroimaging showing polymicrogyria indistinguishable from Zellweger spectrum disease. The parents were confirmed carriers, enabling prenatal diagnosis for subsequent pregnancies.

Ferdinandusse et al. 2006⁶⁶ Ferdinandusse et al. 2006 characterized the mutational spectrum across 110 DBP-deficient patients: N457Y had an allele frequency of ~11% in the patient cohort. Among patients homozygous or compound heterozygous for hydratase-domain mutations, survival ranged from 1 to 26 months. The 8 patients who survived beyond 3 years all carried missense mutations with less structural disruption.

Pierce et al. 2010⁷⁷ Pierce et al. 2010 established that HSD17B4 mutations can cause Perrault syndrome — a milder allelic disorder characterized by sensorineural hearing loss and ovarian dysgenesis in females, without the catastrophic neonatal neurological crisis of classic DBP deficiency. The Perrault phenotype typically arises from compound heterozygous combinations where one allele is a severe loss-of-function and the other is a mild missense; the residual enzymatic activity is sufficient to prevent neonatal catastrophe but insufficient for normal gonadal and auditory development.

ClinVar classifies this variant as Pathogenic/Likely Pathogenic across multiple independent submissions, with functional experimental evidence (protein instability and enzymatic loss) supporting the classification.

Practical Actions

For the vast majority of people, this SNP returns the AA genotype — no pathogenic alleles. The T allele has an estimated global carrier frequency of roughly 1 in 500 to 1 in 1,000, making it the rarest of contexts in consumer genomics.

For heterozygous AT carriers: there is no clinical effect from a single copy. The peroxisomal beta-oxidation capacity of one functional HSD17B4 allele is sufficient for normal metabolic function throughout life. The relevance is exclusively reproductive — if both partners carry a pathogenic HSD17B4 allele (this one or rs137853096 or another), each pregnancy has a 25% chance of producing an affected child with DBP deficiency.

For homozygous TT carriers: this result would only arise in a clinical whole-genome sequencing context in a child with neonatal hypotonia, seizures, and elevated VLCFAs. Supportive care is the current management approach, focused on seizure control, nutritional support, and developmental monitoring.

Interactions

HSD17B4 has two well-characterized pathogenic missense variants: rs137853096 (p.Gly16Ser in the dehydrogenase domain, the most common DBP mutation) and rs137853097 (p.Asn457Tyr in the hydratase domain, the second most common). Compound heterozygosity for these two alleles — one inherited from each parent — is a recognized genotype causing DBP deficiency. In such compound heterozygotes, both enzymatic functions are compromised, typically producing the severe classic presentation. The two variants affect different domains, so neither is a subset of the other's functional defect: the dehydrogenase unit (rs137853096) and the hydratase unit (rs137853097) fail independently, resulting in combined type I/II biochemistry with elevations across VLCFAs, pristanic acid, and bile acid intermediates.

Any person who is a confirmed carrier of rs137853097 should have their partner tested for rs137853096 (and other HSD17B4 pathogenic variants) before conception if a child is planned, as compound heterozygosity is clinically equivalent to homozygosity for either variant alone in terms of reproductive risk.

The aorta tolerates tens of millions of pressure pulses over a lifetime because its wall is reinforced by an elastic scaffold made of microfibrils¹¹ microfibrils
rope-like extracellular matrix structures assembled from fibrillin-1 molecules linked end-to-end, providing elasticity and tensile strength throughout connective tissue. Fibrillin-1 is a 2,871-amino-acid glycoprotein encoded by FBN1 on chromosome 15. It contains 47 epidermal growth factor-like (EGF-like) domains, 43 of which are calcium-binding (cbEGF). Each cbEGF domain requires calcium to fold into a rigid rod — calcium ions are not just incidental cofactors but the structural glue that holds the entire module together. Aspartate residues at conserved positions within these domains directly coordinate the calcium ion, and substituting any one of them disrupts the fold.

The p.Asp1113Gly variant (coding-strand c.3338A>G on the minus-strand FBN1 transcript; plus-strand T→C at chr15:48,487,437) removes the calcium-coordinating aspartate at position 1113 and replaces it with glycine — the smallest amino acid, with no side chain at all. ClinVar classifies this variant as Pathogenic or Likely Pathogenic across three independent submissions (RCV000663632, RCV000802396, RCV002284420), with conditions listed as Marfan syndrome and familial thoracic aortic aneurysm and aortic dissection (FTAAD). The global allele frequency of the C allele is approximately 0.02% (20 of 88,940 ALFA samples), consistent with a rare, high-penetrance disease variant under negative selection.

The Mechanism

Within a cbEGF domain, a conserved sequence motif coordinates a single calcium ion through the side chains of several residues — aspartate residues contribute critically to this coordination shell. Disrupting calcium coordination destabilizes the cbEGF fold²² Disrupting calcium coordination destabilizes the cbEGF fold
Dietz et al. 1993 showed that all early Marfan syndrome missense mutations at that time affected residues with calcium-binding significance in EGF-like domains, preventing fibrillin-1 from achieving the extended rigid conformation needed for microfibril polymerization. The misfolded monomer acts through a dominant-negative mechanism³³ dominant-negative mechanism
the defective protein physically interferes with normal fibrillin-1 assembly, impairing the entire microfibril network even when the second FBN1 allele is intact — which is why a single copy of this variant is sufficient to cause disease.

Weakened microfibrils in the aortic media reduce mechanical resilience of the aortic wall and, importantly, fail to sequester transforming growth factor-beta (TGF-β) in the extracellular matrix. Excess free TGF-β drives smooth muscle cell dysfunction, progressive aortic wall stiffening, and aneurysmal dilation at the sinuses of Valsalva — the anatomical pinch-point where nearly all Marfan-related dissections originate.

The Evidence

The broader clinical evidence base for FBN1 cbEGF domain missense variants predicting aortic disease is well-established:

Tan et al. (Human Molecular Genetics, 2017)⁴⁴ Tan et al. (Human Molecular Genetics, 2017) sequenced FBN1 in 687 patients with sporadic non-syndromic aortic dissection and found pathogenic FBN1 variants in 3.9% (27 patients), the majority being missense mutations — demonstrating that FBN1 pathogenic variants cause FTAAD even in the absence of full syndromic Marfan features.

The most important prognostic data for FBN1 pathogenic variant carriers come from Milleron et al. (JACC, 2020)⁵⁵ Milleron et al. (JACC, 2020): 954 patients with FBN1 pathogenic variants followed over 8,594 patient-years showed that type A aortic dissection occurred at only 0.4 events per 1,000 patient-years when maximum aortic diameter remained below 50 mm on guideline-directed treatment. This is a critically important number: risk is not inevitable but is profoundly modifiable by structured surveillance and timely intervention.

On treatment, Brooke et al. (NEJM, 2008)⁶⁶ Brooke et al. (NEJM, 2008) showed that losartan (an angiotensin receptor blocker that blocks TGF-β pathway overactivation) reduced aortic root dilation rate from 3.54 mm/yr to 0.46 mm/yr in 18 pediatric Marfan patients — approximately an 87% reduction. This finding underpins current guidelines recommending ARBs when aortic root dilation progresses faster than 5 mm/year or root diameter exceeds 40 mm in children.

Practical Actions

The cornerstone of management is annual transthoracic echocardiography to track aortic root diameter at the sinuses of Valsalva. Medical therapy with a beta-blocker (to reduce heart rate and aortic wall stress) or ARB (losartan, to block excess TGF-β signaling) should be initiated at diagnosis or upon detecting progressive dilation. Prophylactic aortic root replacement is recommended when the aortic root approaches 5.0 cm in adults (4.5–5.0 cm in rapid progressors or patients with a family history of dissection).

Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin, moxifloxacin) inhibit lysyl oxidase — the enzyme that cross-links collagen and elastin — and carry an FDA black-box warning for aortic aneurysm rupture and dissection risk, particularly in patients with connective tissue disorders. All prescribers must be informed of this contraindication.

Strenuous isometric exercise (heavy weightlifting, contact sports, competitive athletics) should be avoided — these modalities generate abrupt spikes in arterial pressure that place disproportionate mechanical stress on an already vulnerable aortic wall.

Cascade genetic testing of first-degree relatives is clinically essential. A single positive finding in one family member should trigger testing of all parents, siblings, and adult children, since autosomal dominant transmission gives each relative a 50% chance of carrying the variant — and several may harbor silent aortic dilation detectable only by imaging.

Interactions

FBN1 pathogenic variants, including D1113G, interact clinically with variants in TGF-β pathway genes (TGFBR1, TGFBR2, SMAD2, SMAD3) — the genetic basis of Loeys-Dietz syndrome. Carriers who also harbor pathogenic variants in ACTA2 (smooth muscle alpha-actin) or MYH11 (smooth muscle myosin heavy chain), both associated with independent familial TAAD syndromes, may warrant more aggressive surveillance thresholds, though formal compound genotype data for D1113G specifically are not published.

Other FBN1 cbEGF domain missense variants in the database — including rs193922239 (p.Gly2627Arg) — share the same dominant-negative mechanism and clinical management protocol. The diagnosis of Marfan syndrome versus FTAAD-without-full-Marfan-features depends on the presence of ocular and skeletal manifestations alongside the cardiovascular findings; either presentation requires the same aortic surveillance program.

Fibronectin 1 (FN1) encodes a large glycoprotein that forms the scaffold of the extracellular matrix around blood vessels. In the brain, fibronectin plays a structural role in the neurovascular unit¹¹ neurovascular unit
the interface between blood vessels and neurons, comprising endothelial cells, pericytes, astrocyte endfeet, and neurons, helping maintain blood-brain barrier integrity and coordinating the local response to injury. The rs140926439 variant introduces an amino acid substitution in fibronectin (p.Gly357Glu) that appears to reduce its pathological accumulation at the blood-brain barrier — and in APOE ε4 carriers, this reduction translates into substantially lower Alzheimer's disease risk.

The Mechanism

In APOE ε4 carriers, fibronectin abnormally accumulates in the walls of brain blood vessels²² In APOE ε4 carriers, fibronectin abnormally accumulates in the walls of brain blood vessels
This vascular fibronectin deposition correlates with impaired clearance of toxic amyloid-beta peptides and heightened neuroinflammation. The proposed pathway: APOE ε4 drives excess fibronectin deposition → thickened vascular walls impair gliovascular remodeling and microglial amyloid clearance → amyloid-beta accumulates → neurodegeneration accelerates.

The rs140926439 T allele encodes a Glu (glutamic acid) at position 357 instead of the common Gly (glycine). This Gly→Glu substitution introduces a charged residue into a region of fibronectin involved in matrix assembly, likely disrupting the protein's ability to multimerize or bind to vascular components in the same pathological configuration. Functional studies including zebrafish models support the idea that reduced FN1 function in the neurovascular unit enhances microglial responses and gliovascular remodeling³³ Functional studies including zebrafish models support the idea that reduced FN1 function in the neurovascular unit enhances microglial responses and gliovascular remodeling
Loss-of-function FN1 variants appear to be protective rather than harmful in the context of APOE ε4-driven amyloid accumulation.

The Evidence

The primary evidence comes from a multi-cohort whole-genome sequencing study combining NIA-AD FBS, WHICAP, and EFIGA cohorts, followed by validation in 7,185 APOE ε4 homozygous carriers⁴⁴ The primary evidence comes from a multi-cohort whole-genome sequencing study combining NIA-AD FBS, WHICAP, and EFIGA cohorts, followed by validation in 7,185 APOE ε4 homozygous carriers
Bhattarai et al. (Acta Neuropathologica, 2024) identified rs140926439 as a rare coding protective variant with OR = 0.29 (95% CI 0.11–0.78, p = 0.014), and found it delayed Alzheimer's disease onset by 3.37 years (95% CI 0.42–6.32, p = 0.025) in ε4 carriers. The pathway analysis showed significant enrichment in extracellular matrix processes among protective variants, consistent with FN1's role in vascular matrix biology.

An independent replication using UK Biobank data confirmed the protective signal⁵⁵ An independent replication using UK Biobank data confirmed the protective signal
Lehrer & Rheinstein (Alzheimer Disease and Associated Disorders, 2025) found AD prevalence of 0.43% among APOE ε4 carriers without the variant versus 0.10% among carriers with it — essentially eliminating the ε4 risk increment. The authors propose that fibronectin-driven pathological brain wound-healing may underlie a subset of Alzheimer's cases, and that variants impairing this cascade are protective.

Evidence is classified as emerging: the finding comes from two cohort studies (one discovery + functional validation, one replication), without clinical trial data. The T allele is rare (global frequency ~0.3%), limiting statistical power and making replication in larger datasets essential. The ClinVar classification is "Likely Benign" for the variant in isolation, consistent with its rarity and the context-dependent (APOE ε4-specific) protective effect.

Practical Actions

The T allele confers meaningful protection specifically in APOE ε4 carriers. For CT carriers who are also APOE ε4 positive, this variant provides a counterbalancing protective signal that significantly modifies their overall Alzheimer's risk trajectory. Since the variant is rare and evidence emerging, the actionable value is primarily informational — it informs how aggressively to pursue standard Alzheimer's prevention strategies rather than introducing new interventions specific to this variant alone.

Monitoring for early cognitive changes remains prudent for ε4 carriers regardless of FN1 status, as the T allele reduces but does not eliminate risk.

Interactions

The protective effect of rs140926439 is specifically documented in APOE ε4 carriers (rs429358 C allele + rs7412 C allele combination). Outside of the ε4 context, the variant has not shown significant effect on Alzheimer's risk — the interaction between FN1 and APOE at the neurovascular unit appears central to the mechanism.

Other Alzheimer's risk variants modulating blood-brain barrier function include rs3851179 (PICALM), which affects amyloid-beta transcytosis independently of APOE. An individual carrying both protective rs140926439 and the PICALM protective A allele would theoretically benefit from two complementary blood-brain barrier protection mechanisms, though no direct evidence for this combination exists.